Suzhou Evermed Biomedical Co., Ltd

Evermed Cyclosporine A Homogeneous Enzyme Immunoassay

 *  CLINICAL IMPLICATIONS

    Cyclosporine A (CsA) is a hydrophobic cyclic undecapeptide of fungal origin with immunosuppressive properties ^[1-2].

    CsA is an effective drug for the treatment of certain autoimmune diseases and prevention of tissue rejection following organ transplantation. CsA therapy has optimal safety and efficacy over a narrow range of concentrations and may lead to a number of adverse effects ^[3-4]. The most critical adverse effects are organ rejection from inadequate dosing, or nephrotoxicity and hepatotoxicity when drug concentration becomes too high. CsA is administered either orally or intravenously. Since absorption and hepatic metabolism of the drug are highly variable from patient to patient, there is a poor correlation of blood levels with the administered dose. It is essential to monitor CsA in organ transplantation patients to achieve optimal immunosuppressive effects^[5-6].

 *  TEST SAMPLE TYLE

    Whole Blood

 *   KEY POINTS

• Our assay is Homogenous Enzyme Immunoassay (HEIA), which covers a full range of product portfolio with excellent performance and continuous innovations.
• Ready-to-use reagents that can be loaded on to all kinds of automated chemistry analyzers.
• Assays are liquid-stable and convenient to use —with no waste or reconstitution; no sample preparation and contain nonhazardous preservatives.

*   REFERENCES

[1]Borel. J.F., Cyclosporin A - present experimental status, Transplant Proc 13: 344-348, (1981).

[2]Schreiber, S.L., Chemistry and biology of the immunophilins and their immunosuppressive ligands, Science 251: 283-287, (1991).[3]Sells, R.A., Transplantation Proceedings 15: 2495, (1983).

[4]Alberchtsen, D., Soedal, G., Berg, K.J., Bondevik, H., Brekke, I.B., Fauchald, P., Jakobsen, A., Opedal, B.R. Rugstand, H.E. Thorsby, E., et. al., Cyclosporine in Living Related and Cardaveric Renal Transplantation.

[5]Morris, R.G., Russ, G.R., Cervieeli, M.J. et al., Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin Neoral® at day 7 post-renal transplantation and incidence of rejection in the first month. Ther. Drug Monit. 24(4): 479-485, (2002).

[6]Andrews, D.J., and Cramb, R. Cyclosporin: revisions in monitoring gujidelines and review of current analytic methods. Ann. CLin. Biochem. 39: 424-435, (2002).